Imagine your heart is like a balloon that has stretched too far and can't snap back to pump blood. This project looks at the genetic blueprints of thousands of people with this condition to find the exact 'typos' causing the stretch. By finding these specific errors, they can predict who will get sick and create targeted medicines instead of just treating the symptoms.
Current DCM treatments only manage symptoms and do not address root causes, leaving heart transplantation as the only cure. Additionally, genetic testing lacks the precision needed to predict disease progression accurately.
A comprehensive clinical database and AI-enhanced phenotyping system using imaging and omics data to identify drug targets and improve patient stratification.
If you are a drug discovery firm dealing with a lack of specific targets for heart failure — this project developed a method to identify and validate molecular targets in DCM. This allows for the creation of therapies that address root causes rather than generic symptom management.
If you are a genetic testing laboratory dealing with low predictive accuracy for heart disease — this project developed improved patient stratification using a cohort of 11,750 probands. This enables more precise prediction of disease onset and risk of major cardiac events.
If you are an AI software provider dealing with imprecise cardiac imaging analysis — this project developed AI-based approaches integrating echocardiography and MRI. This improves the phenotyping of heart muscle thinning and stretching.
Based on available project data, no pricing or cost structures are provided as this is a research-funded project.
The project leverages a massive dataset of 11,750 probands and relatives, providing a robust foundation for scaling diagnostic tools and target validation.
Based on available project data, specific licensing terms are not mentioned; however, the project focuses on identifying and validating new therapeutic targets.
The project runs from 2023-10-01 to 2027-09-30, suggesting that validated targets and stratification tools will be available toward the end of this period.
It integrates with standard clinical sites using common imaging modalities like echocardiography, MRI, and electrocardiography.
The consortium is heavily weighted toward research and academia, consisting of 8 partners from 5 countries (DE, ES, FR, NL, UK). With 5 research institutions, 2 universities, and 1 other entity, there is a 0% industry ratio. This indicates the project is currently focused on high-level scientific discovery and validation rather than immediate commercialization.
Contact Stichting Amsterdam UMC regarding cardiogenomics and transcriptomics data
Contact us to identify pharmaceutical partners for the validated DCM targets.
